Fractionated Feridex and positive contrast: In vivo MR imaging of atherosclerosis

Magnetic Resonance in Medicine

Volumn 59, Issue 4, 2008, Pages 721-730

  Briley Saebo, Karen C ^a   Mani, Venkatesh ^a   Hyafil, Fabien ^a   Cornily, Jean Christophe ^a   Fayad, Zahi A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerotic plaque; Iron oxides; Macrophages; Positive contrast; Rabbits

Indexed keywords

BLOOD; DEPOSITION; DISEASES; MACROPHAGES; MAGNETIC RESONANCE IMAGING; PARTICLE SIZE;

ATHEROSCLEROTIC PLAQUE; CRITICAL FACTORS; DOSE-DEPENDENT; IRON DEPOSITION; IRON OXIDE PARTICLES; POSITIVE CONTRAST; RABBITS; SIGNAL ATTENUATION;

IRON OXIDES;

DEXTRAN; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG UPTAKE; HISTOLOGY; LIVER; MACROPHAGE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PLASMA CLEARANCE; PLASMA HALF LIFE; STATISTICAL SIGNIFICANCE;

EID: 41849109517     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.21541     Document Type: Article

References (70)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-126.
2. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995;15:551-561.
3. Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 2005;46:937-954.
4. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84:1381-1478.
5. Choudhury RP, Fuster V, Fayad ZA. Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov 2004;3:913-925.
6. Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006;37:1923-1932.
7. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, Wrenn SP, Narula J. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005;25:2054-2061.
8. Choudhary S, Higgins CL, Chen IY, Reardon M, Lawrie G, Vick GW 3rd, Karmonik C, Via DP, Morrisett JD. Quantitation and localization of matrix metalloproteinases and their inhibitors in human carotid end-arterectomy tissues. Arterioscler Thromb Vasc Biol 2006;26:2351-2358.
9. Sigala F, Georgopoulos S, Papalambros E, Chasiotis D, Vourliotakis G, Niforou A, Kotsinas A, Kavantzas N, Patsouris E, Gorgoulis VG, Bastounis E. Heregulin, cysteine rich-61 and matrix metalloproteinase 9 expression in human carotid atherosclerotic plaques: relationship with clinical data. Eur J Vasc Endovasc Surg 2006;32:238-245.
10. Bennett MR, Evan GI, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 1995;95:2266-2274.
11. de Nooijer R, Verkleij CJ, von der Thusen JH, Jukema JW, van der Wall EE, van Berkel TJ, Baker AH, Biessen EA. Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol 2006;26:340-346.
12. Carr S, Farb A, Pearce WH, Virmani R, Yao JS. Atherosclerotic plaque rupture in symptomatic carotid artery stenosis. J Vasc Surg 1996;23:755-765; discussion 765-756.
13. Virmani R, Burke AP, Kolodgie FD, Farb A. Pathology of the thin-cap fibroatheroma: a type of vulnerable plaque. J Interv Cardiol 2003;16:267-272.
14. Itskovich VV, Samber DD, Mani V, Aguinaldo JG, Fallon JT, Tang CY, Fuster V, Fayad ZA. Quantification of human atherosclerotic plaques using spatially enhanced cluster analysis of multicontrast-weighted magnetic resonance images. Magn Reson Med 2004;52:515-523.
15. Yuan C, Mitsumori LM, Beach KW, Maravilla KR. Carotid atherosclerotic plaque: noninvasive MR characterization and identification of vulnerable lesions. Radiology 2001;221:285-299.
16. Yuan C, Zhao XQ, Hatsukami TS. Quantitative evaluation of carotid atherosclerotic plaques by magnetic resonance imaging, Curr Atheroscler Rep 2002;4:351-357,
17. Herborn CU, Vogt FM, Lauenstein TC, Dirsch Q, Corot C, Robert P, Ruehm SG. Magnetic resonance imaging of experimental atherosclerotic plaque: comparison of two ultrasmall superparamagnetic particles of iron oxide. J Magn Reson Imaging 2006;24:388-393.
18. Yancy AD, Olzinski AR, Hu TC, Lenhard SC, Aravindhan K, Gruver SM, Jacobs PM, Willette RN, Jucker BM. Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling, J Magn Reson Imaging 2005;21:432-442.
19. Hyafil F, Laissy JP, Mazighi M, Tchetche D, Louedec L, Adle-Biassette H, Chillon S, Henin D, Jacob MP, Letourneur D, Feldman LJ. Ferumoxtran-10-enhanced MRI of the hypercholesterolemic rabbit aorta; relationship between signal loss and macrophage infiltration. Arterioscler Thromb Vasc Biol 2006;26:176-181.
20. Schmitz SA, Coupland SE, Gust R, Winterhalter S, Wagner S, Kresse M, Semmler W, Wolf KJ. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest Radiol 2000;35:460-471.
21. Schmitz SA, Taupitz M, Wagner S, Wolf KJ, Beyersdorff D, Hamm B. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J Magn Reson Imaging 2001;14:355-361.
22. Ruehm SG, Corot C, Vogt P, Cristina H, Debatin JF. Ultrasmall superparamagnetic iron oxide-enhanced MR imaging of atherosclerotic plaque in hyperlipidemic rabbits. Acad Radiol 2002;9(Suppl 1):S143-S144.
23. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 2001;103:415-422.
24. Trivedi RA, U-King-Im JM, Graves MJ, Cross JJ, Horsley J, Goddard MJ, Skepper JN, Quartey G, Warburton E, Joubert I, Wang L, Kirkpatrick PJ, Brown J, Gillard JH. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke 2004;35:1631-1635.
25. Trivedi RA, U-King-Im JM, Graves MJ, Kirkpatrick PJ, Gillard JH. Noninvasive imaging of carotid plaque inflammation. Neurology 2004;63:187-188.
26. Wang YXJ, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 2001;11:2319-2331.
27. Yablonskiy DA, Haacke EM. Theory of NMR signal behavior in magnetically inhomogeneous tissues: the static dephasing regime. Magn Reson Med 1994;32:749-763.
28. Mani V, Briley-Saebo KC, Itskovich VV, Samber DD, Fayad ZA. Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP): sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 1.5T and 3T. Magn Reson Med 2006;55:126-135.
29. Mani V, Briley-Saebo KC, Hyafil F, Fayad ZA. Feasibility of in vivo identification of endogenous ferritin with positive contrast MRI in rabbit carotid crush injury using GRASP. Magn Reson Med 2006;56:1096-1106.
30. Seppenwoolde JH, Viergever MA, Bakker CJ. Passive tracking exploiting local signal conservation: the white marker phenomenon. Magn Reson Med 2003;50:784-790.
31. Sirol M, Itskovich VV, Mani V, Aguinaldo JG, Fallon JT, Misselwitz B, Weinmann HJ, Fuster V, Toussaint JF, Fayad ZA. Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation 2004;109:2890-2896.
32. Briley-Saebo K, Hustvedt SO, Haldorsen A, Bjornerud A. Long-term imaging effects in rat liver after a single injection of an iron oxide nanoparticle based MR contrast agent. J Magn Reson Imaging 2004;20:622-631.
33. Briley-Saebo KC, Johansson LO, Hustvedt SO, Haldorsen AG, Bjornerud A, Fayad ZA, Ahlstrom HK. Clearance of iron oxide particles in rat liver: effect of hydrated particle size and coating material on liver metabolism. Invest Radiol 2006;41:560-571.
34. Briley-Saebo KC, Amirbekian V, Mani V, Aguinaldo JGS, Vucic E, Carpenter D, Amirbekian S, Fayad ZA. Gadolinium mixed-micelles: effect of the amphiphile on in vitro and in vivo efficacy in apolipoprotein E knockout mouse models of atherosclerosis. Magn Reson Med 2006;56:1336-1346.
35. Yuan C, Skinner MP, Kaneko E, Mitsumori LM, Hayes CE, Raines EW, Nelson JA, Ross R. Magnetic resonance imaging to study lesions of atherosclerosis in the hyperlipidemic rabbit aorta. Magn Reson Imaging 1996;14:93-102.
36. Yuan C, Kerwin WS. MRI of atherosclerosis. J Magn Reson Imaging 2004;19:710-719.
37. Jung CW, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995;13:661-674.
38. Bjornerud A, Briley-Saebo K, Johansson LO, Kellar KE. Effect of NC100150 injection on the (1)H NMR linewidth of human whole blood ex vivo: dependency on blood oxygen tension. Magn Reson Med 2000;44:803-807.
39. Bjornerud A, Bjerner T, Johansson LO, Ahlstrom HK. Assessment of myocardial blood volume and water exchange: theoretical considerations and in vivo results. Magn Reson Med 2003;49:828-837.
40. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990;175:489-493.
41. Roch A, Gossuin Y, Muller RN, Gillis P. Superparamagnetic colloid suspensions: water magnetic relaxation and clustering. J Magn Magn Mater 2005;293:532-539.
42. Roch A, Muller RN, Gillis P. Theory of proton relaxation induced by superparamagnetic particles. J Chem Phys 1999;110:5403-5411.
43. Koenig SH, Kellar KE. Theory of 1/T-1 and 1/T-2 NMRD profiles of solutions of magnetic nanoparticles. Magn Reson Med 1995;34:227-233.
44. Roch A, Gillis P, Ouakssim A, Muller RN. Proton magnetic relaxation in superparamagnetic aqueous colloids: a new tool for the investigation of ferrite crystal anisotropy. J Magn Magn Mater 1999;201:77-79.
45. Roch A, Muller RN, Gillis P. Water relaxation by SPM particles: neglecting the magnetic anisotropy? A caveat. J Magn Reson Imaging 2001;14:94-96.
46. Majumdar S, Zoghbi SS, Gore JC. Pharmacokinetics of superparamagnetic iron-oxide MR contrast agents in the rat. Invest Radiol 1990;25:771-777.
47. Clement O, Siauve N, Cuenod CA, Frija G. Liver imaging with ferumoxides (Feridex): fundamentals, controversies, and practical aspects. Top Magn Reson Imaging 1998;9:167-182.
48. Clement O, Siauve N, Lewin M, de Kerviler E, Cuenod CA, Frija G. Contrast agents ill magnetic resonance imaging of the liver: present and future. Biomed Pharmacother 1998;52:51-58.
49. Kellar KE, Fujii DK, Gunther WH, Briley-Saebo K, Bjornerud A, Spiller M, Koenig SH. NC100150 injection, a preparation of optimized iron oxide nanoparticles for positive-contrast MR angiography. J Magn Reson Imaging 2000;11:488-494.
50. Muller RN, Gillis P, Moiny F, Roch A. Transverse relaxivity of particulate MRI contrast media: from theories to experiments. Magn Reson Med 1991;22:178-182; discussion 195-176.
51. Tang T, Howarth SP, Miller SR, Trivedi R, Graves MJ, King-Im JU, Li ZY, Brown AP, Kirkpatrick PJ, Gaunt ME, Gillard JH. Assessment of inflammatory burden contralateral to the symptomatic carotid stenosis using high-resolution ultrasmall, superparamagnetic iron oxide-enhanced MRI. Stroke 2006;37:2266-2270.
52. Schmitz SA, Winterhalter S, Schiffler S, Gust R, Wagner S, Kresse M, Coupland SE, Semmler W, Wolf KJ. USPIO-enhanced direct MR imaging of thrombus: preclinical evaluation in rabbits. Radiology 2001;221:237-243.
53. Zheng G, Li H, Zhang M, Lund-Katz S, Chance B, Glickson JD. Low-density lipoprotein reconstituted by pyropheophorbide cholesteryl oleate as target-specific photosensitizer. Bioconjug Chem 2002;13:392-396.
54. Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 2004;126:16316-16317.
55. Zheng G, Chen J, Li H, Glickson JD. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci USA 2005 102:17757-17762.
56. Rensen PC, de Vrueh RL, Kuiper J, Bijsterbosch MK, Biessen EA, van Berkel TJ. Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev 2001;47:251-276.
57. Mitsumori LM, Ricks JL, Rosenfeld ME, Schmiedl UP, Yuan C. Development of a lipoprotein based molecular imaging MR contrast agert for the noninvasive detection of early atherosclerotic disease. Int J Cardiovasc Imaging 2004;20:561-567.
58. Shaish A, Keren G, Chouraqui P, Levkovitz H, Harats D. Imagirg of aortic atherosclerotic lesions by (125)I-LDL, (125)I-oxidized-LDL, (125)I-HDL and (125)I-BSA. Pathobiology 2001;69:225-229.
59. Frias JC, Lipinski MJ, Lipinski SE, Albelda MT. Modified lipoproteins as contrast agents for imaging of atherosclerosis. Contrast Media Mol Imaging 2007;2:16-23.
60. Frias JC, Ma Y, Williams KJ, Fayad ZA, Fisher EA. Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett 2006;6:2220-2224.
61. Rogers WJ, Basu P. Factors regulating macrophage endocytosis of nanoparticles: implications for targeted magnetic resonance plaque imaging. Atherosclerosis 2005;178:67-73.
62. Pouliquen D, Perdrisot R, Ermias A, Akoka S, Jallet P, Le Jeune JJ. Superparamagnetic iron oxide nanoparticles as a liver MRI contrast agent: contribution of microencapsulation to improved biodistribution. Magn Reson Imaging 1989;7:619-627.
63. Pouliquen D, Perroud H, Calza F, Jallet P, Le Jeune JJ. Investigation of the magnetic properties of iron oxide nanoparticles used as contrast agent for MRI. Magn Reson Med 1992;24:75-84.
64. Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, Jacobs P, Lewis J. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol 1989;152:167-173.
65. Weissleder R, Papisov M. Pharmaceutical iron oxides for MR imaging. Rev Magn Reson Med 1992;4:1-20.
66. Jung CW. Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, femmoxtran, ferumoxsil. Magn Reson Imaging 1995;13:675-691.
67. Seneterre E, Weissleder R, Jaramillo D, Reimer P, Lee AS, Brady TJ, Wittenberg J. Bone marrow: ultrasmall superparamagnetic: iron oxide for MR imaging. Radiology 1991;179:529-533.
68. Bellin MF, Webb JA, Van Der Molen AJ, Thomsen HS, Morcos SK. Safety of MR liver specific contrast media. Eur Radiol 2005;15:1607-1614.
69. Briley-Saebo K, Bjornerud A, Grant D, Ahlstrom H, Berg T, Kindberg GM. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging. Cell Tissue Res 2004;316:315-323.
70. Amirbekian V, Lipinski MJ, Briley-Saebo KC, Amirbekian S, Aguinaldo JG, Weinreb DB, Vucic E, Frias JC, Hyafil F, Mani V, Fisher EA, Fayad ZA. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci USA 2007;104:961-966.